Despite COVID-19, we are operating at full capacity and all project work is operating as usual.

Clinically predictive preclinical efficacy testing services at your disposal

SEPTEMBER 15, 2015

Pharmatest Services Ltd approved for French Research Tax Credit

Pharmatest Services Ltd has been approved as an R&D performing organization by French tax authorities. The decision means that French customers of Pharmatest will benefit substantial tax credits when they purchase services of Pharmatest.

Pharmatest Services Ltd (Pharmatest) is a contract research organization that offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. Pharmatest applied the status of an R&D performing organization from French Tax Authorities in June 2015. The tax credit is currently valid until the end of 2020.

Jussi Halleen, CEO of Pharmatest says: “We are very pleased for the approval for French Research Tax Credit. The status of an R&D performing organization will be important for our French customers who will now benefit substantial tax credits for the services they purchase from Pharmatest.”

Transgene S.A. is one French long-term customer to benefit from the R&D performing organization status of Pharmatest. Transgene has been very happy about the many years of collaboration with Pharmatest and recently stated this in a public testimonial.

Dr. Jean-Baptiste Marchand, Head of Proteins Science Group in Transgene says: Transgene and Pharmatest have successfully collaborated since 2009 for the in vitro and in vivo preclinical evaluation of TG’s monoclonal platform in different skeletal diseases. Transgene was particularly impressed by the high professionalism of Pharmatest’s scientist staff, who participated actively nearby our teams in the designs, execution and analysis of the experiments.”